Dr. Aysun Ertaş
Check-ups & DiagnosticsVerified
- 23+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Imaging (MRI, CT, PET)
Somatostatin receptor scintigraphy
What somatostatin receptor scintigraphy is, how radiolabelled analogues detect neuroendocrine tumours, what clinical evidence confirms about diagnostic accuracy, how it compares with Gallium-68 PET-CT and conventional imaging, approximate costs in Turkey against the UK, US and Germany, scan preparation, imaging stages, radiation safety and how to choose an accredited nuclear medicine facility.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Imaging (MRI, CT, PET)
- Hospitals
- 2
- Verified
- 2
- Price from
- Price on request
Verified surgeons for Somatostatin Receptor Scintigraphy
2 doctors Compare doctors, ratings and prices — ask any of them for a free quote.
Uzm. Dr. Türkan Özer
Check-ups & DiagnosticsVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Somatostatin receptor scintigraphy in Turkey: what it is and how it works
Somatostatin receptor scintigraphy (SRS), historically known as an Octreoscan, is a specialised nuclear medicine scan used to detect, stage and monitor neuroendocrine tumours (NETs). Neuroendocrine tumour cells typically display high concentrations of somatostatin receptors on their surface, especially subtype 2 (SSTR2). During this scan, a tiny, safe dose of a radiolabelled somatostatin analogue—most commonly Indium-111 pentetreotide or a Technetium-99m peptide—is injected into your bloodstream. The tracer binds selectively to these receptor sites on abnormal cells. A gamma camera or single-photon emission computed tomography (SPECT) scanner then detects the emitted radiation, producing detailed functional maps of tumour tissue. For patients arranging diagnostic checks abroad, explore our checkup treatments in Turkey.
Hospitals in Turkey perform SRS to locate primary tumours, identify metastases and assess suitability for targeted radionuclide therapies. This guide explains how the scan works, what evidence supports it, approximate costs, preparation, recovery and how to choose an accredited centre.
How does somatostatin receptor scintigraphy detect neuroendocrine tumours?
The scan relies on molecular affinity. Well-differentiated neuroendocrine tumours overexpress somatostatin receptors at levels far higher than healthy tissue. When injected, the synthetic radiotracer binds directly to these receptor targets. While organs such as the spleen, kidneys, liver and bladder show normal physiological clearance, focal areas of high tracer concentration outside these organs indicate potential tumour sites.
Imaging teams combine two-dimensional planar scans with three-dimensional SPECT/CT. While planar images provide a broad survey, SPECT/CT rotates around you to merge functional radioactive signals directly with low-dose anatomical CT slices. This helps physicians distinguish tumour lesions in lymph nodes from normal background activity in nearby bowel loops.
Does somatostatin receptor scintigraphy work: clinical accuracy and evidence
Clinical guidelines from the European Neuroendocrine Tumor Society (ENETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) confirm that somatostatin receptor scintigraphy achieves diagnostic sensitivity between 60% and 85% for well-differentiated gastroenteropancreatic neuroendocrine tumours and bronchial carcinoids. It offers high diagnostic specificity for confirming neuroendocrine origin, staging disease extent before surgery and monitoring recurrence.
However, SRS has recognized limitations. Sensitivity decreases for tumours smaller than one centimetre due to gamma camera resolution limits. High-grade, poorly differentiated neuroendocrine carcinomas often lose their somatostatin receptors, making FDG PET-CT a more suitable choice. Furthermore, insulinomas frequently lack adequate receptor density, yielding false negatives in over half of cases. An honest clinical team will select imaging based on your tumour grade and histology.
Somatostatin receptor scintigraphy cost in Turkey compared with the UK, US and Germany
The figures below show approximate cost ranges for complete scintigraphy protocols, including radiopharmaceutical preparation, multi-day scanning and specialist physician reporting. Final prices depend on whether SPECT/CT is used and individual hospital fees. Each hospital provides an itemised quote in writing.
| Country | Approximate cost range |
|---|---|
| Turkey | €900 – €2,400 |
| United Kingdom | €2,200 – €5,500 |
| United States | €3,500 – €9,000 |
| Germany | €2,000 – €5,200 |
What influences the somatostatin receptor scintigraphy price: the radiopharmaceutical itself represents the largest expense, requiring dedicated radiopharmacy preparation. Other variables include whether hybrid SPECT/CT is added and the extent of specialist consultations. Standard packages in Turkey typically include pre-scan lab checks, tracer administration, two-day imaging sessions, official physician reports, English translations and local clinic transfers. Request an estimate through our free quote service.
Somatostatin receptor scintigraphy compared with Gallium-68 PET-CT and standard scans
Physicians evaluate several diagnostic modalities when investigating suspected neuroendocrine conditions, choosing based on resolution needs, clinical urgency and scanner availability.
| Diagnostic modality | Best suited to | Typical limits |
|---|---|---|
| Somatostatin receptor scintigraphy (SRS / SPECT) | Staging well-differentiated NETs and checking receptor status when PET is unavailable | Lower resolution; less sensitive for lesions under 1 cm; requires 24 to 48 hours |
| Gallium-68 DOTATATE PET-CT | Detecting small primary tumours, occult lymph nodes and bone metastases | Higher cost; requires specialized regional tracer production; limited global access |
| Contrast-enhanced CT or MRI | Anatomical mapping, surgical planning and liver lesion sizing | Evaluates structural dimensions only; cannot confirm cellular receptor biology |
Unlike structural imaging like mammography, which assesses tissue density, nuclear scintigraphy tracks functional cellular receptors. While Gallium-68 PET-CT offers higher resolution and completes in one day, somatostatin receptor scintigraphy remains an internationally trusted standard, particularly where PET tracers are unavailable or for verifying receptor status before peptide receptor radionuclide therapy (PRRT).
Who is a candidate for somatostatin receptor scintigraphy, and who is not?
Good candidates include adults with confirmed or suspected well-differentiated neuroendocrine tumours of the stomach, bowel, appendix, pancreas or lungs. It is widely used to identify primary tumour sites in patients with elevated markers like chromogranin A, detect metastases, assess surgical outcomes and confirm receptor avidity before targeted radionuclide therapy. Many patients coordinate imaging alongside broader checkup treatments in Turkey.
The scan is not suitable during pregnancy due to fetal radiation risks; pregnancy must be ruled out beforehand. Nursing mothers must pause breastfeeding and discard milk temporarily. It is also unsuitable for patients with severe kidney impairment who cannot clear the tracer efficiently, or those with known allergies to octreotide compounds. Patients with high-grade, receptor-negative neuroendocrine carcinomas generally require alternative imaging such as FDG PET-CT.
How to prepare and what happens during the scan step by step
Proper preparation ensures accurate results. If taking short-acting octreotide, you may be asked to pause it for 24 to 48 hours before imaging. Patients on long-acting analogues (such as octreotide LAR or lanreotide) typically schedule the scan 3 to 4 weeks after their last injection, just before their next dose, so medication does not block receptor sites. Drink plenty of water before and after injection to promote tracer clearance. A mild laxative is often recommended the night before day-two imaging to clear physiological bowel activity.
The examination follows these steps:
- Tracer injection: On day one, a nurse inserts a small intravenous line and administers the radiolabelled analogue. The injection takes seconds and causes no sensation.
- Initial imaging: About 4 hours later, you lie on the scanner couch while the gamma camera sweeps your body for 30 to 45 minutes.
- Rest period: You leave the clinic, eat normally and drink fluids to flush unabsorbed tracer.
- 24-hour imaging: On day two, you return for second-phase scans. Background activity has cleared, yielding high-contrast images. SPECT/CT of the abdomen or chest takes 45 to 60 minutes.
Somatostatin receptor scintigraphy recovery, travel timelines and radiation safety
Because this is a non-invasive imaging scan with no sedation, somatostatin receptor scintigraphy recovery is immediate. You can eat, take routine medications and resume non-strenuous daily routines right away. Drinking extra water over the first two days helps your kidneys eliminate residual tracer. Simple precautions like washing hands thoroughly and flushing twice ensure household safety.
For patients travelling to Turkey, plan a trip of 3 to 4 nights to cover consultation, day-one injection and day-two SPECT/CT scanning. You can fly home comfortably after day-two imaging; your hospital provides an official certificate explaining that medical imaging was performed, in case airport monitors detect trace radioactivity. Review how it works before booking your flights.
Risks, side effects and safety considerations
Somatostatin receptor scintigraphy has an established safety profile supported by guidelines from the UK National Health Service (NHS), the European Association of Nuclear Medicine (EANM) and the US Food and Drug Administration (FDA). The radiation dose from Indium-111 pentetreotide averages 10 to 12 millisieverts (mSv), comparable to a standard abdominal and pelvic CT scan. Technetium-99m protocols deliver approximately 4 to 6 mSv.
Adverse reactions occur in fewer than 1% of patients and are usually mild, such as brief dizziness, mild nausea or flushing. In patients with active carcinoid syndrome, tracer injection can very rarely cause a transient flare of flushing or blood pressure changes. Nuclear medicine departments keep standard octreotide medication available to manage this symptom promptly.
Diagnostic results: what scans show and what they cannot confirm
Understanding what scintigraphy reveals is essential. Scans provide functional metabolic data: dark areas (hot spots) indicate where radiolabelled analogues have bound to somatostatin receptors. A positive result confirms somatostatin-avid tissue, pinpointing primary tumours or metastases in the liver, bones or lymph nodes.
However, the scan cannot determine exact cellular grade, Ki-67 proliferation index or tumour margins. It confirms receptor presence but does not replace a tissue biopsy for initial diagnosis. Conversely, a negative scan does not rule out all malignancy; it simply indicates that lesions lack sufficient SSTR2 receptors for gamma camera detection. Doctors always evaluate scan findings alongside CT or MRI images, clinical symptoms and blood tumour markers.
How to choose an accredited nuclear medicine centre in Turkey and red flags
Choosing a reputable hospital ensures clinical safety and accurate results. Ensure the facility in Turkey is licensed by the Ministry of Health and holds international accreditation (such as JCI or ISO). The nuclear medicine unit should operate modern gamma cameras with SPECT/CT capability and employ certified nuclear medicine specialists.
Questions to ask your clinic before travelling:
- Which radiotracer will be used for my scan?
- Does your department use hybrid SPECT/CT for anatomical overlay?
- How should I adjust my somatostatin analogue medication before arriving?
- Will I receive full digital DICOM images and an English medical report before flying home?
- Does a multidisciplinary neuroendocrine tumour board review complex cases?
Red flags include clinics offering planar scans without SPECT/CT, failure to review your medications beforehand, quotes omitting radiotracer costs, or lack of specialist physician reporting. Contact our team through our free quote page to receive a verified hospital proposal.
Hospitals with Check-ups & Diagnostics in Turkey
Frequently asked questions
Somatostatin receptor scintigraphy is a nuclear medicine imaging scan that identifies neuroendocrine tumours by detecting somatostatin receptors on abnormal cells. A small amount of a radiolabelled peptide is injected into your bloodstream, and specialised gamma or SPECT/CT cameras capture images showing where tumours are located throughout the body.
It works effectively for well-differentiated neuroendocrine tumours that overexpress type-2 somatostatin receptors, achieving diagnostic sensitivity between 60% and 85%. However, it is less sensitive for tumours smaller than one centimetre, insulinomas, or poorly differentiated, high-grade neuroendocrine carcinomas that lack surface receptors, which require alternative PET-CT scans.
Approximate costs in Turkey typically range between €900 and €2,400, compared with €2,200 to €5,500 in the UK and up to €9,000 in the US. The total price depends on whether hybrid SPECT/CT is included, the specific radiopharmaceutical used and pre-scan consultations. Hospitals provide an itemised quotation in writing.
While CT and MRI display anatomical structures and organ dimensions, somatostatin receptor scintigraphy displays functional cellular activity. It highlights whether abnormal masses actively express somatostatin receptors, which helps oncologists confirm tumour biology, detect hidden metastases and assess eligibility for targeted peptide receptor radionuclide therapy (PRRT).
Recovery is immediate, and you can resume customary daily activities straight after each imaging session. Drinking plenty of fluids over the first 48 hours speeds up the elimination of the radiotracer through the kidneys. Practising basic hygiene, such as washing hands thoroughly and flushing twice, ensures household safety.
The scan itself does not cause pain. You will feel only a minor pinprick during the initial intravenous injection of the radiotracer, similar to a routine blood test. Lying flat and still on the padded scanner table for 30 to 45 minutes can feel slightly stiff, but the cameras cause no physical discomfort.
Scan findings provide an accurate baseline of your tumour distribution and receptor expression at that specific point in time. Because neuroendocrine tumours often grow slowly, results remain clinically relevant for several months, although repeat imaging is typically scheduled after six to twelve months or whenever symptoms or biochemical markers change.
Yes, it is considered very safe by international nuclear medicine societies. The effective radiation dose is comparable to a standard diagnostic abdominal CT scan. Allergic reactions occur in fewer than one per cent of patients, and the radiotracer clears rapidly through natural urinary excretion within two to three days.
Gallium-68 PET-CT offers higher spatial resolution, detects lesions under one centimetre and completes within a single day. However, somatostatin receptor scintigraphy remains an accurate, globally validated and cost-effective standard where PET radiotracers are unavailable or when evaluating receptor avidity for long-acting somatostatin analogue management.
Patients generally stay three to four nights in Turkey. The imaging protocol spans two consecutive days: the radiotracer injection and initial images on day one, followed by definitive 24-hour SPECT/CT scans on day two. This schedule allows time for arrival, consultations, scanning and receiving your final specialist report.
Patient stories